KR100980749B1 - 페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물 - Google Patents
페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물 Download PDFInfo
- Publication number
- KR100980749B1 KR100980749B1 KR1020090125899A KR20090125899A KR100980749B1 KR 100980749 B1 KR100980749 B1 KR 100980749B1 KR 1020090125899 A KR1020090125899 A KR 1020090125899A KR 20090125899 A KR20090125899 A KR 20090125899A KR 100980749 B1 KR100980749 B1 KR 100980749B1
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- fenofibrate
- pharmaceutical composition
- starch
- weight
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
- B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
Abstract
Description
성분 | 600mg/tab. | 중량비(%) | |
과립 | 페노피브레이트 | 120.0 | 20.00 |
폴록사머 407 | 84.0 | 14.00 | |
비타민 E TPGS | 36.0 | 6.00 | |
PVP K12 | 20.0 | 3.33 | |
우르소데옥시콜린산 | 5.99 | 1.00 | |
덱스트린 | 200.0 | 33.33 | |
정제 | 에오로실 200 | 14.01 | 2.34 |
락토오즈 | 100.0 | 16.67 | |
Ac-Di-Sol | 19.3 | 3.22 | |
마그네슘 스테아레이트 | 0.7 | 0.12 |
성분 | 실시예 2 | 실시예 3 | 실시예 4 | ||||
600 mg/tab. |
중량비 (%) |
600 mg/tab. |
중량비 (%) |
600 mg/tab. |
중량비 (%) |
||
과립 | 페노피브레이트 | 120.0 | 20.00 | 120.0 | 20.00 | 120.0 | 20.00 |
폴록사머 407 | 60.0 | 10.00 | 60.0 | 10.00 | 60.0 | 10.00 | |
크레모포어 EL | 40.0 | 6.67 | - | - | - | - | |
크레모포어 RH40 | - | - | 40.0 | 6.67 | - | - | |
트윈 80 | - | - | - | - | 40.0 | 6.67 | |
PVP K12 | 20.0 | 3.33 | 20.0 | 3.33 | 20.0 | 3.33 | |
콜린산 | 10.0 | 1.67 | - | - | - | - | |
데옥시콜린산 | - | - | 10.0 | 1.67 | - | - | |
케노데옥시콜린산 | - | - | - | - | 10.0 | 1.67 | |
덱스트린 | 200.0 | 33.33 | 200.0 | 33.33 | 200.0 | 33.33 | |
정제 | 에어로실 200 | 15.0 | 2.50 | 15.0 | 2.50 | 15.0 | 2.50 |
덱스트린 | 100.0 | 16.67 | 100.0 | 16.67 | 100.0 | 16.67 | |
Ac-Di-Sol | 30.0 | 5.00 | 30.0 | 5.00 | 30.0 | 5.00 | |
마그네슘 스테아레이트 | 5.0 | 0.83 | 5.0 | 0.83 | 5.0 | 0.83 |
Claims (8)
- 페노피브레이트; 현탁화제; 및 우르소데옥시콜린산, 타우로콜린산, 데옥시콜린산, 콜린산, 리토콜린산, 케노데옥시콜린산, 히오데옥시콜린산, 트리하이드록시 코프로스탄산, 및 글리코콜린산으로 이루어진 군으로부터 1종 이상 선택된 담즙산 또는 그의 염; 및 수용성 당류를 포함하는 수성 현탁액을 분무건조하여 얻어진 과립을 포함하는 정제 또는 캡슐제 형태의 약학 조성물.
- 제1항에 있어서, 상기 현탁화제가 솔비탄 에스테르, 폴리옥시에틸렌 솔비탄 지방산 에스테르, 자당 지방산 에스테르, 폴리에틸렌 글리콜-15-히드록시스테아레이트, 폴리옥시에틸렌 글리콜화 천연 또는 수소화 피마자유, 폴리옥시에틸렌-폴리옥시프로필렌 공중합체, 합성 비타민 E 유도체, 폴리옥시에틸렌 알킬 에스테르, 지방산 마크로골 글리세라이드, 폴리글리세릴 지방산 에스테르, 레시틴, 글리세릴 지방산 에스테르, 및 폴리옥시에틸렌 스테아레이트로 이루어진 군으로부터 1종 이상 선택되는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서, 상기 현탁화제의 함량이 상기 페노피브레이트 1 중량부에 대하여 0.3 ∼ 3 중량부인 것을 특징으로 하는 약학 조성물.
- 삭제
- 제1항에 있어서, 상기 담즙산 또는 그의 염의 함량이 상기 페노피브레이트 1 중량부에 대하여 0.05 ∼ 0.5 중량부인 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서, 상기 수용성 당류가 덱스트린, 포도당, 폴리덱스트로스, 전분, 호화전분, 옥수수전분, 감자전분, 및 유당으로 이루어진 군으로부터 1 종 이상 선택되는 것을 특징으로 하는 약학 조성물.
- 제1항에 있어서, 상기 수용성 당류의 함량이 상기 페노피브레이트 1 중량부에 대하여 0.3 ∼ 4 중량부인 것을 특징으로 하는 약학 조성물.
- 삭제
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090125899A KR100980749B1 (ko) | 2009-12-17 | 2009-12-17 | 페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090125899A KR100980749B1 (ko) | 2009-12-17 | 2009-12-17 | 페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100980749B1 true KR100980749B1 (ko) | 2010-09-07 |
Family
ID=43009839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090125899A KR100980749B1 (ko) | 2009-12-17 | 2009-12-17 | 페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물 |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100980749B1 (ko) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030206949A1 (en) | 1998-11-20 | 2003-11-06 | Skyepharma Canada Inc. | Dispersible phospholipid stabilized microparticles |
US6696084B2 (en) | 2000-09-20 | 2004-02-24 | Rtp Pharma Inc. | Spray drying process and compositions of fenofibrate |
US7255877B2 (en) | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
US20080286354A1 (en) * | 2000-04-19 | 2008-11-20 | Thomas Julius Borody | Composition and therapies for hyperlipidaemia-associated disorders |
-
2009
- 2009-12-17 KR KR1020090125899A patent/KR100980749B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7255877B2 (en) | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
US20030206949A1 (en) | 1998-11-20 | 2003-11-06 | Skyepharma Canada Inc. | Dispersible phospholipid stabilized microparticles |
US20080286354A1 (en) * | 2000-04-19 | 2008-11-20 | Thomas Julius Borody | Composition and therapies for hyperlipidaemia-associated disorders |
US6696084B2 (en) | 2000-09-20 | 2004-02-24 | Rtp Pharma Inc. | Spray drying process and compositions of fenofibrate |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI741106B (zh) | 葡萄糖激酶活化劑的口服製劑及其製備方法 | |
US10034854B2 (en) | Pharmaceutical composition with improved bioavailability | |
ES2713157T3 (es) | Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato | |
US20220233701A1 (en) | Solid compositions comprising a glucokinase activator and methods of making and using the same | |
US20100011610A1 (en) | Fluidized spray drying | |
JP2021525741A (ja) | グルコキナーゼ活性化剤およびppar受容体活性化剤を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 | |
WO2012043709A1 (ja) | 難溶性薬物の溶解性改善製剤 | |
KR20100126452A (ko) | 난용성 약물용 약학적 조성물 | |
US20140066473A1 (en) | Modified release compositions comprising tacrolimus | |
JP5479909B2 (ja) | 新規製剤 | |
AU2019329905B2 (en) | Vitamin D pediatric dosage forms, methods of making and using | |
JP2021059551A (ja) | フェニルアミノピリミジン誘導体を含む医薬組成物 | |
JP2019163327A (ja) | 三種混合製剤 | |
US20190248830A1 (en) | Proliposomal testosterone undecanoate formulations | |
US20110097414A1 (en) | Pharmaceutical compositions comprising adsorbate of fenofibrate | |
US20110311625A1 (en) | Solid dosage forms of fenofibrate | |
KR100980752B1 (ko) | 담체 표면 상에 흡착된 페노피브레이트를 포함하는 과립 및 이를 포함하는 약학 조성물 | |
KR100980749B1 (ko) | 페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물 | |
KR102104507B1 (ko) | 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법 | |
US20100317642A1 (en) | Pharmaceutical composition of orlistat | |
JP2022506622A (ja) | 6-(1-アクリロイルピペリジン-4-イル)-2-(4-フェノキシフェニル)ニコチンアミドを含有する非晶質固体分散体 | |
JP2007504190A (ja) | 3−[(2−{[4−(ヘキシルオキシカルボニルアミノ−イミノ−メチル)−フェニルアミノ]−メチル}−1−メチル−1h−ベンズイミダゾール−5−カルボニル)−ピリジン−2−イル−アミノ]−エチルプロピオネート及びそれらの塩の新規経口投与形態 | |
WO2016195377A2 (ko) | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 | |
WO2017035263A1 (en) | Compositions comprising a plasma kallikrein inhibitor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130718 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140821 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20150811 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160811 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170727 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181004 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190827 Year of fee payment: 10 |